Research Coverage
Analyst Coverage
Kairos Pharma, Ltd. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Kairos Pharma, Ltd.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kairos Pharma, Ltd. or its management. Kairos Pharma, Ltd. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Firm
Analyst
Jason Kolbert
D. Boral Capital
Prostate Cancer Trial Expands Beyond Cedars
Department of Defense Funds Kairos Pharma’s ENV205 Research, Strengthening Drug Development Pipeline
Evidence for KROS 101 and KROS 401 in Melanoma and Glioblastoma
ASCO Data on KROS101 a Small Molecule GITR Ligand Agonist
Promising Interim P2 Data for ENV105
Kairos Pharma Readies ESMO 2025 Presentation of Encouraging Phase 2 Safety and Early Efficacy Data
Kairos Pharma Highlights Interim Phase 2 Data for ENV-105 in Advanced Prostate Cancer
Kairos Shareholder Update: Advancing ENV105 and Expanding Oncology Portfolio
Jason Kolbert
Rodman and Renshaw
Tony Butler
Jason McCarthy
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Related links
Technologies
Explore our innovative technologies, advanced platforms, and groundbreaking solutions driving breakthroughs in cancer treatment and addressing critical unmet medical needs.
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
Research Coverage
Analyst Coverage
Kairos Pharma, Ltd. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Kairos Pharma, Ltd.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kairos Pharma, Ltd. or its management. Kairos Pharma, Ltd. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Firm: EF Hutton
Analyst: Jason Kolbert
Overcoming Hurdles in Immune Suppression and Drug Resistance
Firm: D. Boral Capital
Analyst: Jason Kolbert
Prostate Cancer Trial Expands Beyond Cedars
Department of Defense Funds Kairos Pharma’s ENV205 Research, Strengthening Drug Development Pipeline
Evidence for KROS 101 and KROS 401 in Melanoma and Glioblastoma
ASCO Data on KROS101 a Small Molecule GITR Ligand Agonist
Promising Interim P2 Data for ENV105
Kairos Pharma Readies ESMO 2025 Presentation of Encouraging Phase 2 Safety and Early Efficacy Data
Kairos Pharma Highlights Interim Phase 2 Data for ENV-105 in Advanced Prostate Cancer
Kairos Shareholder Update: Advancing ENV105 and Expanding Oncology Portfolio
Firm: Rodman and Renshaw
Analyst: Tony Butler
Related links
Technologies
Pipeline
Explore our drug development pipeline, showcasing innovative therapies and cutting-edge technologies aimed at addressing unmet medical needs and transforming patient outcomes.
Investors
Access key investor information, financial updates, strategic plans, and insights into our mission to drive innovation and deliver transformative therapies in cancer research and treatment.
